Clinical efficacy of citalopram alone or augmented with bupropion in methadone-stabilized patients

American Journal on Addictions

Volumn 16, Issue 3, 2007, Pages 187-194

  Poling, James ^a,d   Pruzinsky, Rhonda ^a   Kosten, Thomas R ^b   Gonsai, Kishorchandra ^a   Sofuoglu, Mehmet ^a   Gonzalez, Gerardo ^a   Oliveto, Alison ^c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^d VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; CITALOPRAM; METHADONE; PLACEBO;

ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METHADONE TREATMENT; OPIATE ADDICTION; OUTPATIENT; POPULATION RESEARCH; RANDOMIZATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANALGESICS, OPIOID; ANXIETY DISORDERS; BUPROPION; CITALOPRAM; COCAINE-RELATED DISORDERS; DEPRESSIVE DISORDER; DOPAMINE UPTAKE INHIBITORS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHADONE; MIDDLE AGED; OPIOID-RELATED DISORDERS; SEROTONIN UPTAKE INHIBITORS;

EID: 34347381688     PISSN: 10550496     EISSN: 15210391     Source Type: Journal    
DOI: 10.1080/10550490701375640     Document Type: Article

References (37)

1. Best D, Gossop M, Stewart D, Marsden J, Lehmann P, Strang J. Continued heroin use during methadone treatment: relationships between frequency of use and reasons reported for heroin use. Drug Alcohol Depend. 1999;53:191-195.
2. Maxwell S, Shinderman MS. Optimizing long-term response to methadone maintenance treatment: a 152-week follow-up using higher-dose methadone. J Addict Dis. 2002;21:1-12.
3. Oliveto AH, Feingold A, Schottenfeld R, Jatlow P, Kosten TR. Desipramine in opioid-dependent cocaine abusers maintained on buprenorphine vs methadone. Arch Gen Psychiatry. 1999;56: 812-820.
4. Nunes EV, Quitkin FM, Donovan SJ, et al. Imipramine treatment of opiate-dependent patients with depressive disorders. A placebo-controlled trial. Arch Gen Psychiatry. 1998;55:153-160.
5. Vaswani M, Linda FK, Ramesh S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:85-102.
6. Batki SL, Manfredi LB, Sorensen JL, Jacob P, Dumontet R, Jones RT. Fluoxetine for cocaine abuse in methadone patients: preliminary findings. NIDA Res Monogr. 1991;105:516-517.
7. Oliveto A, Kosten TR, Schottenfeld RS, Ziedonis D, Falcioni J. Desipramine, amantadine, or fluoxetine in buprenorphine-maintained cocaine users. J Subst Abuse Treat. 1995;12:423-428.
8. Petrakis I, Carroll KM, Nich C, Gordon L, Kosten T, Rounsaville B. Fluoxetine treatment of depressive disorders in methadone-maintained opioid addicts. Drug Alcohol Depend. 1998;50:221-226.
9. Kosten TR, Morgan CM, Falcione J, Schottenfeld RS. Pharmacotherapy for cocaine-abusing methadone-maintained patients using amantadine or desipramine. Arch Gen Psychiatry. 1992;49:894-898.
10. Oliveto A. The efficacy of sertraline augmented with bupropion in cocaine-dependent patients with depressive symptoms. In: Kampman K, Pettinati H (Chairs). Combinations of Medications for the Treatment of Drug Addiction. Symposium conducted at the meeting of the College on Problems of Drug Dependence; June 2005; Orlando, Fla.
11. Kampman KM, Leiderman D, Holmes T, et al. Cocaine Rapid Efficacy Screening Trials (CREST): lessons learned. Addiction. 2005; 100 (Suppl. 1):102-110.
12. Carpenter KM, Brooks AC, Vosburg SK, Nunes EV. The effect of sertraline and environmental context on treating depression and illicit substance use among methadone maintained opiate dependent patients: a controlled clinical trial. Drug Alcohol Depend. 2004;74:123-134.
13. Bodkin JA, Lasser RA, Wines JA Jr, Gardner DM, Baldessarini RJ. Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. J Clin Psychiatry. 1997;58:137-145.
14. Spier SA. Use of bupropion with SRIs and venlafaxine. Depress Anxiety. 1998;7:73-75.
15. Boyer WF, Feighner JP. The combined use of fluoxetine and bupropion. Paper presented at: 146th Annual Meeting of the American Psychiatry Association; May 27, 1993; San Francisco, Calif.
16. Ferris RM, Beaman OJ. Bupropion: a new antidepressant drug, the mechanism of action of which is not associated with downregulation of postsynaptic beta-adrenergic, serotonergic (5-HT2), alpha 2-adrenergic, imipramine and dopaminergic receptors in brain. Neuropharmacology. 1983;22:1257-1267.
17. Modell JG, Katholi CR, Modell JD, DePalma RL. Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline. Clin Pharmacol Ther. 1997;61:476-487.
18. Walker PW, Cole JO, Gardner EA, et al. Improvement in fluoxetine-associated sexual dysfunction in patients switched to bupropion. J Clin Psychiatry. 1993;54:459-465.
19. Ashton AK, Rosen RC. Bupropion as an antidote for serotonin reuptake inhibitor-induced sexual dysfunction. J Clin Psychiatry. 1998;59:112-115.
20. Labbate LA, Grimes JB, Hines A, Pollack MH. Bupropion treatment of serotonin reuptake antidepressant-associated sexual dysfunction. Ann Clin Psychiatry. 1997;9:241-245.
21. Goodnick PJ, Goldstein BJ. Selective serotonin reuptake inhibitors in affective disorders, I: Basic pharmacology. J Psychopharmacol. 1998;12(3 Suppl. B):S5-S20.
22. Carroll KM. Cognitive-behavioral coping skills treatment for cocaine dependence. Yale University Psychotherapy Development Center, 1996. Unpublished manual.
23. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV. Patient Edition. Washington, DC: American Psychiatric Press, Inc.; 1995.
24. McLellan AT, Kushner H, Metzger D, et al. The fifth edition of the Addiction Severity Index. J Subst Abuse Treat. 1992b;9(3):199-213.
25. Radloff LS. The CES-D Scale: a self-report depression scale for research in the general population. Applied Psychological Measurement. 1977;I:385-401.
26. Hamilton MA. A rating scale for depression. Journal of Neurology, Neurosurgery, & Psychiatry. 1960;23:56-62.
27. Endicott J, Cohen J, Nee J, Fleiss J, Sarantakos S. Hamilton Depression Rating Scale. Extracted from regular and change versions of the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry. 1981;38:98-103.
28. Kearns NP, Cruickshank CA, McGuigan KJ, Riley SA, Shaw SP, Snaith RP. A comparison of depression rating scales. Br J Psychiatry. 1982;141:45-49.
29. Gibbons RD, Hedeker D, Elkin I, et al. Some conceptual and statistical issues in analysis of longitudinal psychiatric data. Application to the NIMH Treatment of Depression Collaborative Research Program dataset. Arch Gen Psychiatry. 1993;50:739-750.
30. Bryk AS, Raudenbush SW. Application of hierarchical linear models to assessing change. Psychol Bull. 1987;101:147-158.
31. Hedeker D, Gibbons RD. MIXOR: a computer program for mixed-effects ordinal regression analysis. Comput Methods Programs Biomed. 1996;49:157-176.
32. Woody GE, O'Brien CP, McLellan AT, Marcovici M, Evans BD. The use of antidepressants with methadone in depressed maintenance patients. Ann NY Acad Sci. 1982;398:120-127.
33. Kleber HD,Weissman MM, Rounsaville BJ,Wilber CH, Prusoff BA, Riordan CE. Imipramine as treatment for depression in addicts. Arch Gen Psychiatry. 1983;40:649-653.
34. Titievsky J, Seco G, Barranco M, Kyle AM. Doxepin as adjunctive therapy for depressed methadone maintenance patients: a double-blind study. J Clin Psychiatry. 1982;43:454-456.
35. Woody GE, O'Brien CP, Rickels K. Depression and anxiety in heroin addicts: a placebo-controlled study of doxepin in combination with methadone. Am J Psychiatry. 1975;132:447-450.
36. Kosten T, Oliveto A, Feingold A, et al. Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients. Drug Alcohol Depend. 2003;70:315-325.
37. Poling J, Oliveto A, Petry N, et al. Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population. Arch Gen Psychiatry. 2006;63:219-228.